The US Food and Drug Administration (FDA) has approved GE Healthcare’s digital subtraction angiography (DSA) imaging software AngioViz.
GE Healthcare said AngioViz gives doctors a new visualization of vascular flow on a single image to help them make important decisions during complex interventional radiology procedures.
Using a technique called parametric imaging, AngioViz looks at each pixel in the image series and determines the peak value of opacification caused by the contrast and the time it takes for that pixel to reach peak opacification.
This enables doctors to perceive parameters of flow to support decision-making.
In addition, AngioViz allows easy comparison of parametric images from different DSA acquisitions, such as pre- and post-treatment images.
This can help physicians understand the impact on flow dynamics of various interventional treatments.